Cell News and Research

RSS

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

New understanding of muscle growth and repair

Revealing another part of the story of muscle development, Johns Hopkins researchers have shown how the cytoskeleton from one muscle cell builds finger-like projections that invade into another muscle cell’s territory, eventually forcing the cells to combine.

5 Jun 2011

New skin cancer drug brings hope

A new drug for the dreaded cancer melanoma is in the horizon. It is called Vemurafenib. This is a class of drug that cancer researchers are applauding today at the American Society of Clinical Oncology's annual meeting in Chicago.

5 Jun 2011

Scientists use super microscope to pinpoint body’s immunity ‘switch’

Using the only microscope of its kind in Australia, medical scientists have been able for the first time to see the inner workings of T-cells, the front-line troops that alert our immune system to go on the defensive against germs and other invaders in our bloodstream.

5 Jun 2011

Scientists to reveal latest research breakthroughs at 'Chemistry and Health' conference

To mark the International Year of Chemistry, the 94th Canadian Chemistry Conference and Exhibition will take place at the Palais des congr-s de Montr-al from June 5 to 9, 2011. The gathering is the biggest ever annual event in Canada to focus on science and the practice of chemistry.

4 Jun 2011

DFG to form new collaborative research centers as of 1 July 2011

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish 21 new Collaborative Research Centres (CRCs) as of 1 July 2011. This was decided by the relevant Grants Committee at its spring meeting in Bonn.

4 Jun 2011

Scientists find way to protect kidney from cancer drug toxicity

Scientists may have a way to make the powerful cancer drug cisplatin less toxic to the kidneys and more effective against some cancers.

4 Jun 2011

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

Life Technologies Corporation today announced that preliminary data from DNA sequencing performed in cooperation with the University Hospital Muenster, Germany, on the Ion Personal Genome Machine strongly suggests that the bacterium at the root of the deadly outbreak in Germany is a new hybrid type of pathogenic E. coli strains.

4 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

Dendritic cells secrete signal molecule that contributes to pathogenesis of atherosclerosis

Atherosclerosis is the most common cause of cardiovascular disease, and results from chronic inflammation of arterial vessel walls. An international collaboration led by Professor Christian Weber of Ludwig-Maximilians-Universität (LMU) in Munich and Privatdozentin Alma Zernecke of Würzburg University now shows that dendritic cells stimulate this process by derailing a mechanism that normally acts as a brake on immune reactions.

4 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Genentech, a member of the Roche Group and Astellas Pharma US, Inc., today announced results of EURTAC, the first Phase III study with Tarceva in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC).

4 Jun 2011

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

4 Jun 2011

MreB protein molecules assemble into larger units in bacterial cell wall

Almost all bacteria owe their structure to an outer cell wall that interacts closely with the supporting MreB protein inside the cell. As scientists at the Max Planck Institute for Biochemistry and at the French INRA now show, MreB molecules assemble into larger units, but not - as previously believed - into continuous helical structures.

4 Jun 2011

Maryland researchers deny link between cell phone radiation and brain cancer

University of Maryland researchers in the A. James Clark School of Engineering have expressed concerns regarding the validity of recent findings announced in the Journal of the American Medical Association and a World Health Organization panel suggesting that radiation from cell phones may be carcinogenic.

4 Jun 2011

Enzyme Research journal publishes new peer-reviewed article involving Protandim

LifeVantage Corporation, the maker of Protandim, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim was published in the scientific journal Enzyme Research.

4 Jun 2011

Cell News and Research

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

New understanding of muscle growth and repair

New skin cancer drug brings hope

Scientists use super microscope to pinpoint body’s immunity ‘switch’

Scientists to reveal latest research breakthroughs at 'Chemistry and Health' conference

DFG to form new collaborative research centers as of 1 July 2011

Scientists find way to protect kidney from cancer drug toxicity

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Dendritic cells secrete signal molecule that contributes to pathogenesis of atherosclerosis

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

MreB protein molecules assemble into larger units in bacterial cell wall

Maryland researchers deny link between cell phone radiation and brain cancer

Enzyme Research journal publishes new peer-reviewed article involving Protandim

Johns Hopkins researchers solve long-standing mystery of Warburg effect

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

Scientists demonstrate why B cells exposed to chronic HIV shut down, how they can be reactivated

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News